Ftse Mib
34.433,37
-1,12%
DAX
18.679,03
-0,47%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
71.080,30
-0,51%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aura Biosciences Inc (AURA) Aura Biosciences Inc (AURA) Notizie

AURA

Aura Biosciences (AURA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AURA
DataOraFonteTitoloSimboloCompagnia
09/05/202413:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AURAAura Biosciences Inc
09/05/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
09/05/202413:00GlobeNewswire Inc.Aura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
08/05/202413:00GlobeNewswire Inc.Aura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
27/03/202412:00Business WireAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
04/03/202423:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
02/02/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
07/12/202314:00Business WireAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
09/11/202322:05Business WireAura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
07/11/202322:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AURAAura Biosciences Inc
07/11/202304:02Business WireAura Biosciences Announces Pricing of Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
06/11/202322:08Business WireAura Biosciences Announces Proposed Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
06/11/202321:50Dow Jones NewsAura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-SarNASDAQ:AURAAura Biosciences Inc
06/11/202321:00Business WireAura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
31/10/202321:05Business WireAura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023NASDAQ:AURAAura Biosciences Inc
24/10/202302:51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
02/10/202322:05Business WireAura Biosciences Strengthens and Expands Leadership Team with Key AppointmentsNASDAQ:AURAAura Biosciences Inc
09/08/202313:00Business WireAura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
09/06/202322:58Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AURAAura Biosciences Inc
07/06/202323:47Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:AURAAura Biosciences Inc
07/06/202322:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AURAAura Biosciences Inc
12/05/202313:00Business WireAura Biosciences to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:AURAAura Biosciences Inc
11/05/202322:28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AURAAura Biosciences Inc
11/05/202322:10Business WireAura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
25/04/202322:07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AURAAura Biosciences Inc
25/04/202322:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AURAAura Biosciences Inc
15/03/202321:48Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AURAAura Biosciences Inc
15/03/202321:38Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AURAAura Biosciences Inc
15/03/202321:10Business WireAura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
16/02/202313:00Business WireAura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal AdministrationNASDAQ:AURAAura Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AURA

La tua Cronologia

LSE
15DD
Anz Bank 43
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network